A cohort study in three Scandinavian countries found no significant increase in thyroid cancer risk with glucagon-like peptide 1 receptor agonists.
A cohort study using data from nationwide registers in Denmark, Norway, and Sweden between 2007 and 2021 included 145,410 patients who initiated GLP-1 RAs and 291,667 propensity score-matched patients initiating dipeptidyl peptidase 4 inhibitors as active comparators.
Additional analysis included 111,744 who initiated GLP-1 RAs and 148,179 patients initiating sodium-glucose cotransporter 2 inhibitors.During follow-up, there were 76 incident thyroid cancer cases among GLP-1 RA users and 184 cases in DPP4 inhibitor users, giving incidence rates per 10,000 of 1.33 and 1.46, respectively, a nonsignificant difference .
In the SGLT2 inhibitor comparison, there was also no significantly increased thyroid cancer risk for GLP-1 RAs ."Given the upper limit of the confidence interval, the findings are incompatible with more than a 31% increased relative risk of thyroid cancer. In absolute terms, this translates to no more than 0.36 excess cases per 10 000 person-years, a figure that should be interpreted against the background incidence of 1.
Thyroid Carcinoma Cancer Of The Thyroid Thyroid Disorder Thyroid Disease Thyroid Dysfunction Malignant Head And Neck Neoplasm Head And Neck Cancer Head And Neck Cancer (HNC) Papillary Carcinoma Of The Thyroid Papillary Thyroid Carcinoma Cancer Risk Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Thyroid GLP-1 Receptor Agonists
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How these weight loss drugs offer benefits beyond the scaleGLP-1 receptor agonist drugs named the 2023 Breakthrough of the Year
Read more »
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study SuggestsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study SuggestsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »
Gaps Found in Appropriate SGLT2, GLP-1 PrescribingA trio of new studies showed that SGLT2 inhibitors and GLP-1 agonists are often not prescribed or accessible to people who could benefit from them.
Read more »
Study Finds No Evidence of Thyroid Cancer Risk from GLP-1 AnaloguesA Swedish study of over 435,000 people has found no evidence to support concerns that long-term use of GLP-1 analogues, such as Wegovy and Ozempic, increases the risk of thyroid cancer.
Read more »
New Study Reveals Detailed Protein Structure of Bitter Taste ReceptorResearchers have discovered the protein structure of TAS2R14, a bitter taste receptor, and how bitter-tasting substances activate it. This breakthrough could pave the way for the development of drugs targeting taste receptors.
Read more »